July 28, 2014

Biologic treatments for RA carry similar infection risk

effrey R. Curtis, M.D., from the University of Alabama at Birmingham, and colleagues utilized 1998 to 2011 data from the U.S. Veterans Health Administration to identify RA patients initiating rituximab, abatacept, or anti-tumor necrosis factor (anti-TNF) therapy. The authors sought to assess the comparative risk of hospitalized infection associated with anti-TNF and non-anti-TNF biologic agents.

UAB in the News

 
 
Back to Top